- Companies join forces bringing together Bristol Myers Squibb’s (BMS) deep oncology and clinical
development expertise and Tubulis’ differentiated and unique approach to Antibody-Drug-
Conjugate (ADC) design with the goal of delivering the true therapeutic potential of ADCs - Tubulis to receive upfront payment of $22.75 million and milestone payments potentially
totaling over $1 billion plus tiered royalties on net product sales - BMS to obtain access to Tubulis’ proprietary P5 conjugation and Tubutecan platforms to develop
versatile and customizable antibody-drug conjugates for cancer treatment
MUNICH, GERMANY, April 20, 2023 – Tubulis and Bristol Myers Squibb (NYSE: BMY) today announced
that they have entered into a strategic license agreement to develop differentiated antibody-drug
conjugates (ADCs).
Through the license agreement, Bristol Myers Squibb will gain exclusive rights to access Tubulis’
Tubutecan payloads in combination with Tubulis’ proprietary P5 conjugation platform for the
development of a selected number of highly differentiated ADCs to treat solid tumors. P5 and
Tubutecans facilitate the generation of ultra-stable ADCs that have the potential to actively reduce
unwanted target-independent toxicities and are optimized for on-target delivery of potent
topoisomerase-1 inhibitors.
The terms of the agreement include an upfront payment of $22.75 million to Tubulis in addition to the
potential for over $1 billion in development, regulatory, and commercial milestone payments plus
royalty payments on resulting marketed products. Following antibody target selection by Bristol Myers
Squibb, Tubulis will provide the company with its linker-payload to generate a uniquely matched ADC
for each antibody. Bristol Myers Squibb will assume sole responsibility for development,
manufacturing, and commercialization of the resulting ADC candidates.
“This strategic agreement with Bristol Myers Squibb is an important validation of the potential of our
approach in developing next-generation ADC-based therapeutics and our cutting-edge ADC
conjugation technologies that accommodate advanced ADC design to tackle tumors with high-unmet
medical need,” said Dominik Schumacher, PhD, CEO and co-founder of Tubulis. “We are committed to
transforming oncology treatment paradigms and to deliver better outcomes for cancer patients.
Joining forces with BMS, a leading global oncology company, is a significant step towards achieving
that goal.”
“ADCs play a promising role in cancer therapy, and Tubulis’ differentiated technologies offer
opportunities to overcome current challenges in the development of safe and effective ADC
therapeutics,” said Emma Lees, PhD, Senior Vice President, Research and Early Development and Head,
Mechanisms of Cancer Resistance Thematic Research Center at Bristol Myers Squibb. “With the P5
platform, we will be able to pair the right antibody with the right payload and thus provide potential
for meaningful therapeutic benefits for patients with solid tumors. We are looking forward to a fruitful
partnership with the Tubulis team.”
About Tubulis
Tubulis generates uniquely matched protein-drug conjugates through the combination of novel
proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic
potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming
constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its growing
pipeline and will continue to collaborate with industry partners to usher in a new ADC era and deliver
better outcomes for patients. Visit www.tubulis.com or follow us on LinkedIn and Twitter.
Contacts
For Tubulis
Dominik Schumacher, CEO & Co-Founder
Phone: + 49 (0) 175 8005594
Email: contact@tubulis.com
Media Requests for Tubulis
Trophic Communications
Stephanie May or Marie Weickert
Phone: +49 (0) 171 1855682
Email: tubulis@trophic.eu